Qiagen N.V. (QGEN)
After hours:
| Previous close | 46.15 |
| Open | 46.43 |
| Bid | 46.39 x 900 |
| Ask | 46.41 x 800 |
| Day's range | 46.12 - 46.51 |
| 52-week range | 40.38 - 51.18 |
| Volume | |
| Avg. volume | 668,338 |
| Market cap | 10.564B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 25.08 |
| EPS (TTM) | 1.85 |
| Earnings date | 24 Apr 2023 - 28 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.04 |
- Simply Wall St.
With 83% ownership, Qiagen N.V. (NYSE:QGEN) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
- Zacks
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals. The SBTi is a global body that enables companies to set ambitious emissions reductions target
